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of diabetic patients enrolled. Ours was a prospective randomized
study. By randomizing the patients prior to their procedure, the
possibility of bias was negated. As noted in our Table 1, no
significant differences existed between groups in any patient
characteristic (including cardioplegia type, diabetes, and beta-
blocker use) (3).
Both groups demonstrated an equal number of diabetics, use of
beta-blockers, and cold or warm blood cardioplegia. Therefore, the
differences between the groups seen at the conclusion of the study
cannot be attributed to any of these factors. As Dr. Bisleri and
colleagues state, there was an equal number of diabetics in both
groups (35% vs. 31%; p  NS) (3). Although this number of
diabetic patients is higher than expected for the general popula-
tion, we were evaluating bypass patients in whom a higher
incidence of diabetes is expected. As there were no significant
differences in the patient characteristics, the effect on atrial
fibrillation seen at the conclusion of the study is separate and
significant.
Finally, the concern that “off-pump” bypass surgery decreases a
“well-known” risk of atrial fibrillation is relevant to our study.
During “off-pump” bypass, there is no cross-clamp applied, and
minimal if any anterior fat pad dissection occurs. We agree that
this may be one of the factors reducing the risk of atrial fibrillation
using this approach.
In summary, the prospective randomized design of our study
should address the concerns of Dr. Bisleri and colleagues. We
agree that this study generates many questions regarding the
mechanism of postoperative atrial fibrillation, and we look forward
to future studies. The reality is that the sample size was small and
although the patients were randomized, dogmatic conclusions are
not warranted, at least not yet.
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Cardiac Complications of Vaccines
We read with interest the recent study by Eckart et al. (1) entitled
“Incidence and Follow-Up of Inflammatory Cardiac Complica-
tions After Smallpox Vaccination.” Although smallpox is the most
common vaccine that is associated with myocarditis, other vaccines
have also been linked with myocarditis, such as diphtheria–
tetanus–polio vaccine, tetanus vaccine alone, cholera, typhoid–
cholera, and variola vaccines (2–6). In order to assess any relation-
ship between smallpox vaccination and myocarditis more
accurately, it would be essential to know what other vaccines were
administered to the military personnel in the study. Moreover, was
there any relationship between specific lot numbers and myocarditis?
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REPLY
We appreciate the comments of Dr. Kula and colleagues regarding
our publication on vaccinia-associated myocarditis (1). We agree
with the need to consider the possible contributions of other
vaccinations to myocarditis, and we recognize the potential for
confounding. Our group recently published data revealing no
statistically significant association of development of vaccinia-
associated myocarditis in those with concomitant administration of
other vaccines (2). Other vaccines in addition to vaccinia in cases
of myocarditis may have included anthrax, typhoid, hepatitis A,
hepatitis B, influenza, meningococcal, MMR (measles, mumps,
rubella), poliovirus, and yellow fever vaccines. No association was
seen between specific lot numbers and development of myocarditis.
We note that all the available references cited by Kula and
colleagues were isolated case reports relating to other vaccines
(3–6). Although they raise interesting questions, the reported
observations are less persuasive than the extended case series we
have reported (1,2). Recognizing that our experience is not within
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